Immunology and inflammation biotech company Bambusa (BBTX.US) has set its IPO price at $15-$17 per share, aiming to raise $150 million.

Bambusa Therapeutics, a biotech company focused on immunology and inflammation, announced the terms of its initial public offering (IPO) on Monday. The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. At the midpoint of the proposed price range, Bambusa Therapeutics would have a fully diluted market value of $837 million. The company plans to list on Nasdaq under the ticker symbol "BBTX." The IPO is expected to be priced in the week of October 26, 2026. Headquartered in Boston, Massachusetts, Bambusa Therapeutics is a clinical-stage biotech company developing long-acting bispecific antibodies for immunological and inflammatory diseases. Its lead candidate, BBT001, targets IL-4R and IL-31 and is currently in a Phase I trial for atopic dermatitis, with preliminary proof-of-concept data announced in July 2026; it is also in a Phase IIa trial in China for chronic spontaneous urticaria. The company's second candidate, BBT002, targets IL-4R and IL-5 and is currently in Phase I to Phase IIa trials for chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, and asthma. In addition, the company has two preclinical programs: BBT003 targets TL1A and IL-23p19 for the treatment of inflammatory bowel disease; BBT004 is a B-cell-depleting bispecific antibody for the treatment of autoimmune diseases. Bambusa Therapeutics' core assets are all licensed from the Chinese subsidiary of German biotech company BioNTech.